Maze Therapeutics (NASDAQ:MAZE) Reaches New 52-Week High – Still a Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s share price hit a new 52-week high during trading on Wednesday . The company traded as high as $31.93 and last traded at $29.52, with a volume of 280001 shares trading hands. The stock had previously closed at $29.75.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on MAZE shares. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Maze Therapeutics in a research note on Thursday, September 18th. JPMorgan Chase & Co. increased their price target on Maze Therapeutics from $27.00 to $37.00 and gave the company an “overweight” rating in a research note on Monday, September 29th. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research note on Wednesday, October 8th. BTIG Research upped their price objective on Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Finally, Guggenheim upped their price objective on Maze Therapeutics from $19.00 to $34.00 and gave the company a “buy” rating in a research report on Monday, September 15th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $33.83.

Maze Therapeutics Stock Performance

The business has a 50-day simple moving average of $21.32 and a 200-day simple moving average of $15.14.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.02.

Insider Buying and Selling at Maze Therapeutics

In other news, Director Richard H. Scheller sold 20,744 shares of the stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $22.37, for a total value of $464,043.28. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. New York State Common Retirement Fund purchased a new stake in shares of Maze Therapeutics in the first quarter worth approximately $25,000. CWM LLC purchased a new stake in shares of Maze Therapeutics in the second quarter worth approximately $28,000. Corebridge Financial Inc. purchased a new stake in shares of Maze Therapeutics in the first quarter worth approximately $48,000. Legal & General Group Plc raised its holdings in shares of Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after buying an additional 3,371 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Maze Therapeutics by 452.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock worth $57,000 after buying an additional 3,774 shares during the period.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.